Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL789189

O=S(=O)(O)C(F)(F)F.c1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA7 P43166 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
PTPN1 P18031 3/20 0.39
TSHR P16473 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
CA5A P35218 2/20 0.35
CA9 Q16790 1/20 0.35
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
CES1 P23141 1/20 0.32
HSD11B1 P28845 1/20 0.30
GPR3 P46089 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL30552135 1.00 ALDH1A1 (0.50) ALDH1A1L3MBTL1CA1CA2CA7
Trifluoromethanesulfonic Acid SCHEMBL27902845 0.97 ALDH1A1 (0.48) ALDH1A1L3MBTL1CA1CA2CA7
Trifluoromethanesulfonic Acid SCHEMBL28220121 0.97 ALDH1A1 (0.48) ALDH1A1L3MBTL1CA1CA2CA7
Trifluoromethanesulfonic Acid SCHEMBL596728 0.97 ALDH1A1 (0.48) ALDH1A1L3MBTL1CA1CA2CA7
Trifluoromethanesulfonic Acid SCHEMBL28188456 0.91 ALDH1A1 (0.43) ALDH1A1L3MBTL1CA1CA2CA7
Trifluoromethanesulfonic Acid SCHEMBL39465 0.89 ALDH1A1 (0.50) ALDH1A1L3MBTL1CA1CA2CA7
Trifluoromethanesulfonic Acid SCHEMBL295 0.89
Trifluoromethanesulfonic Acid SCHEMBL3507077 0.89
Trifluoromethanesulfonic Acid SCHEMBL3950101 0.89
Trifluoromethanesulfonic Acid SCHEMBL25292879 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3956321-B1 PROCESS FOR PREPARING AXITINIB, PROCESS FOR PURIFYING THE INTERMEDIATE 2-((3-IODO-1H-INDAZOL-6-YL)THIO)-N-METHYLBENZAMIDE, PROCESS FOR PURIFYING AXITINIB VIA THE AXITINIB HCL SALT, SOLID FORM OF THE AXITINIB HCL SALT SYNTHON BV (NL) 2024-03-20 EP claimed
CN-115716805-A Method for asymmetric catalytic synthesis of chiral pyrazolone derivative containing propargyl alcohol structural fragment 重庆医科大学 2023-02-28 CN claimed
CN-115385948-A Spiro-dihydrobenzothiole bisoxazoline compound, preparation method and application thereof 中国科学院上海有机化学研究所 2022-11-25 CN claimed
CN-110669097-B Synthesis method of oleanoline derivative 北京赫尔默技术有限公司 2020-12-08 CN claimed
CN-110669097-A Synthesis method of oleanoline derivative 北京赫尔默技术有限公司 2020-01-10 CN claimed
EP-2855419-A1 NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS Boehringer Ingelheim International GmbH (DE) 2015-04-08 EP claimed
WO-2013178575-A1 NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-12-05 WO claimed
CN-119371419-A PKMYT1 kinase inhibitors 杭州邦顺制药有限公司 2025-01-28 CN disclosed
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2024-06-20 US disclosed
EP-4364570-A1 HETEROCYCLIC COMPOUND AND RESISTANT HARMFUL ARTHROPOD-CONTROLLING METHOD FOR COMPOSITION CONTAINING SAME Sumitomo Chemical Company Limited (JP) 2024-05-08 EP disclosed
CN-115716805-B Asymmetric catalytic synthesis method of chiral pyrazolone derivative containing propargyl alcohol structural fragment 重庆医科大学 2024-05-07 CN disclosed
CN-115716805-B Asymmetric catalytic synthesis method of chiral pyrazolone derivative containing propargyl alcohol structural fragment 重庆医科大学 2024-05-07 CN disclosed
US-11866428-B2 Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (GB) 2024-01-09 US disclosed
US-20040235667-A1 Pyrazolyl-substituted thienyloxypyridines BASF AKTIENGESELLSCHAFT (DE) 2004-11-25 US disclosed
US-20040181075-A1 Process of making chalcone derivatives GENERAL ELECTRIC COMPANY 2004-09-16 US disclosed
US-20040143139-A1 Process for the production of aminodiphenylamines LANXESS DEUTSCHLAND GMBH (DE) 2004-07-22 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003090912-A9 PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2004-01-08 WO disclosed
WO-2003090912-A1 PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-11-06 WO disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040143139-A1 Process for the production of aminodiphenylamines NUDT1, ITPA, NAAA ALDH1A1 693/4885L3MBTL1 4675/4885CA1 3079/4885
US-20040235667-A1 Pyrazolyl-substituted thienyloxypyridines HDHD5, CBR3, KCNH3 ALDH1A1 2329/4885L3MBTL1 820/4885CA1 4430/4885
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 ALDH1A1 1493/4885L3MBTL1 1230/4885CA1 2764/4885
US-11866428-B2 Bicyclic heterocycle compounds and their uses in therapy H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 ALDH1A1 1493/4885L3MBTL1 1230/4885CA1 2764/4885
US-20040181075-A1 Process of making chalcone derivatives CYP2B6, LSS, CYP2E1 ALDH1A1 828/4885L3MBTL1 1678/4885CA1 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.